Established · publishing since 1972Rising activity
Cancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsCutaneous Melanoma Detection and ManagementMelanoma and MAPK PathwaysCAR-T cell therapy research
Publications
106
Citations
1,742
Est. group size
~1
Recurring co-author estimate
Active years
55
Publishing since 1972
In context
Among 4,953 established Medicine PIs within our index
Citations: 1,742p25 789 · p75 7,423 · cohort median 2,544
Publications / year (recent): 13.8p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~10 · 5% small-team papers (≤3 authors) · across 22 venues
Publication cadence
Publications per year over the last 10 years — averaging 13.8/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Supplementary Figure 8 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Supplementary Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Supplementary Table 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Supplementary Figure 7 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Supplementary Figure 3 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Supplementary Figure 1 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Supplementary Figure 5 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Supplementary Figure 2 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Data from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
- Figure 4 from Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma
2026
Publishes in
- Journal of Clinical Oncology×16
- Regular and Young Investigator Award Abstracts×6
- Pigment Cell & Melanoma Research×3
- Journal of Immunotherapy×3
- Immunotherapy×2
Similar researchers
By research-topic overlap
- Kai He
Medicine · The Ohio State University
- Siming Li
Medicine · University of Michigan
- Leslie A. Fecher
Medicine · University of Michigan
- Christopher D. Lao
Medicine · University of Michigan
- Douglas B. Johnson
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile